ReviewCurrent opinion in virology2022
Bacteriophage T4 as a nanovehicle for delivery of genes and therapeutics into human cells.
Review in Current opinion in virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.Vaccines · 2026Review
- Functional Blood-Brain Barrier Crossing by Biomimetic M13 Phage Vectors for Targeted Neuronal Delivery.Advanced healthcare materials · 2026Article
- The biology of jumbo phages.Nature communications · 2026Review
- Prevalent gut phages encode modular adhesins mediating epithelial binding and endoplasmic reticulum trafficking.Nature communications · 2026Article
- Cryo-EM structures of bacteriophage T4 portal-neck assembly intermediates reveal a viral genome retention mechanism.Nature communications · 2026Article
- CRISPR-Cpf1-Mediated T4 Phage Genome Editing for One-Step In Vivo Display of Heterologous Protein.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Bacteriophage T4 genome packaging: mechanism and application.EcoSal Plus · 2025Review
- The bacteriophage T4 replisome: a model system for understanding DNA replication mechanisms.EcoSal Plus · 2025Review
- Advancements inMolecules (Basel, Switzerland) · 2024Review
- Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform.Annual review of virology · 2024Review
- Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.Journal of nanobiotechnology · 2024Review
- The untapped potential of phage model systems as therapeutic agents.Virus evolution · 2024Article
- The Next Generation of Drug Delivery: Harnessing the Power of Bacteriophages.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Structure and Function of Hoc-A Novel Environment Sensing Device Encoded by T4 and Other Bacteriophages.Viruses · 2023Article
- Design of bacteriophage T4-based artificial viral vectors for human genome remodeling.Nature communications · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The ability to deliver therapeutic genes and biomolecules into a human cell and restore a defective function has been the holy grail of medicine. Adeno-associated viruses and lentiviruses have been extensively used as delivery vehicles, but their capacity is limited to one (or two) gene(s). Bacteriophages are emerging as novel vehicles for gene therapy. The large 120 × 86-nm T4 capsid allows engineering of both its surface and its interior to incorporate combinations of DNAs, RNAs, proteins, and their complexes. In vitro assembly using purified components allows customization for various applications and for individualized therapies. Its large capacity, cell-targeting capability, safety, and inexpensive manufacturing could open unprecedented new possibilities for gene, cancer, and stem cell therapies. However, efficient entry into primary human cells and intracellular trafficking are significant barriers that must be overcome by gene engineering and evolution in order to translate phage-delivery technology from bench to bedside.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.